Omega-3 supplementation associated with reductions in cardiovascular events; benefit most consistent at higher EPA+DHA doses (≥2 g/day) and in high-risk populations.

High-dose omega-3 (≥2 g EPA+DHA/day) consistently reduces fasting triglycerides by 15–30% in adults with elevated baseline levels.

Omega-3 PUFA supplementation produced a statistically significant reduction in DOMS (MD −0.93, 95% CI −1.44 to −0.42; p=0.0004) across 12 RCTs, though the effect size fell below the minimal clinically important difference of 1.4 on a 10-point VAS. Low-quality evidence overall.

CoQ10 100 mg three times daily over 2 years reduced major adverse cardiovascular events (15% vs 26% placebo) and all-cause mortality (10% vs 18% placebo; RR 0.58, 95% CI 0.35–0.95) in addition to standard therapy.

CoQ10 supplementation significantly improved statin-associated muscle pain (WMD −1.60), weakness (WMD −2.28), cramps (WMD −1.78), and tiredness (WMD −1.75) across 12 RCTs (n=575), though plasma creatine kinase was not significantly reduced.